MX2010008397A - Inhibidores del receptor de quimioquinas cxcr3. - Google Patents
Inhibidores del receptor de quimioquinas cxcr3.Info
- Publication number
- MX2010008397A MX2010008397A MX2010008397A MX2010008397A MX2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A
- Authority
- MX
- Mexico
- Prior art keywords
- chemokine receptor
- inhibitors
- cxcr3
- receptor cxcr3
- benzsulphonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Esta invención se dirige a un compuesto 3-(amido o sulfamido)-4-(4-azinil sustituido)benzamida o benzosulfonamida como se define en la presente memoria. El compuesto 3-(amido o sulfamido)-(4-azinil sustituido)benzamida o benzosulfonamida es útil como un inhibidor del receptor de quimioquinas CxCR3, y para prevenir o tratar una enfermedad mediada por el receptor de quimioquinas CxCR3 o afección relacionada con la misma en un paciente que lo necesite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2973808P | 2008-02-19 | 2008-02-19 | |
PCT/US2009/034340 WO2009105435A1 (en) | 2008-02-19 | 2009-02-18 | Inhibitors of the chemokine receptor cxcr3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010008397A true MX2010008397A (es) | 2010-08-23 |
Family
ID=40527535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010008397A MX2010008397A (es) | 2008-02-19 | 2009-02-18 | Inhibidores del receptor de quimioquinas cxcr3. |
Country Status (25)
Country | Link |
---|---|
US (1) | US8268828B2 (es) |
EP (1) | EP2262784B1 (es) |
JP (1) | JP2011512412A (es) |
KR (1) | KR20100123835A (es) |
CN (1) | CN102007108A (es) |
AR (1) | AR070430A1 (es) |
AU (1) | AU2009215643A1 (es) |
BR (1) | BRPI0908815A2 (es) |
CA (1) | CA2715557A1 (es) |
CL (1) | CL2009000368A1 (es) |
CO (1) | CO6241113A2 (es) |
CR (1) | CR11604A (es) |
DO (1) | DOP2010000254A (es) |
EC (1) | ECSP10010409A (es) |
IL (1) | IL207597A0 (es) |
MA (1) | MA32191B1 (es) |
MX (1) | MX2010008397A (es) |
NI (1) | NI201000132A (es) |
NZ (1) | NZ587380A (es) |
PE (1) | PE20091576A1 (es) |
RU (1) | RU2010138577A (es) |
SV (1) | SV2010003648A (es) |
TW (1) | TW200948791A (es) |
WO (1) | WO2009105435A1 (es) |
ZA (1) | ZA201005314B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
WO2010126811A1 (en) | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
WO2011084985A1 (en) * | 2010-01-07 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
KR101251788B1 (ko) | 2010-12-06 | 2013-04-08 | 기아자동차주식회사 | 차량 연비 정보 단말표시 시스템 및 그 방법 |
US9181226B2 (en) * | 2011-07-18 | 2015-11-10 | Merck Patent Gmbh | Benzamides |
EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
JP6219844B2 (ja) * | 2012-01-10 | 2017-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 卵胞刺激ホルモンの調節因子としてのベンズアミド誘導体 |
ES2632237T3 (es) | 2012-02-02 | 2017-09-12 | Idorsia Pharmaceuticals Ltd | Compuestos de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados |
EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
WO2015011099A1 (en) | 2013-07-22 | 2015-01-29 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
KR102496364B1 (ko) * | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Smyd 억제제 |
JP6337218B2 (ja) | 2015-01-15 | 2018-06-06 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Cxcr3受容体調節剤としてのヒドロキシアルキル−ピペラジン誘導体 |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
WO2018183145A1 (en) | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2052541A5 (es) | 1969-06-13 | 1971-04-09 | Takeda Chemical Industries Ltd | |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
US20050272936A1 (en) | 2002-06-03 | 2005-12-08 | Axten Jeffrey M | Imidazolium cxcr3 inhibitors |
US6734659B1 (en) | 2002-06-13 | 2004-05-11 | Mykrolis Corporation | Electronic interface for use with dual electrode capacitance diaphragm gauges |
US7417045B2 (en) * | 2005-02-16 | 2008-08-26 | Schering Corporation | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity |
AU2006214378A1 (en) * | 2005-02-16 | 2006-08-24 | Pharmacopeia, Inc. | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
WO2007002742A1 (en) | 2005-06-28 | 2007-01-04 | Pharmacopeia, Inc. | Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders |
CN101341147A (zh) | 2005-10-11 | 2009-01-07 | 先灵公司 | 具有cxcr3拮抗剂活性的取代的杂环化合物 |
US20090143413A1 (en) | 2005-11-29 | 2009-06-04 | Adams Alan D | Thiazole Derivatives as CXCR3 Receptor Modulators |
EP1996577B1 (en) | 2006-03-21 | 2016-02-10 | Merck Sharp & Dohme Corp. | Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity |
AU2007272884A1 (en) | 2006-07-14 | 2008-01-17 | Pharmacopeia, Inc. | Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity |
PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
-
2009
- 2009-02-17 PE PE2009000232A patent/PE20091576A1/es not_active Application Discontinuation
- 2009-02-18 JP JP2010547712A patent/JP2011512412A/ja active Pending
- 2009-02-18 CL CL2009000368A patent/CL2009000368A1/es unknown
- 2009-02-18 MX MX2010008397A patent/MX2010008397A/es not_active Application Discontinuation
- 2009-02-18 RU RU2010138577/04A patent/RU2010138577A/ru not_active Application Discontinuation
- 2009-02-18 AR ARP090100561A patent/AR070430A1/es not_active Application Discontinuation
- 2009-02-18 CA CA2715557A patent/CA2715557A1/en not_active Abandoned
- 2009-02-18 WO PCT/US2009/034340 patent/WO2009105435A1/en active Application Filing
- 2009-02-18 NZ NZ587380A patent/NZ587380A/en not_active IP Right Cessation
- 2009-02-18 EP EP09711984.6A patent/EP2262784B1/en active Active
- 2009-02-18 KR KR1020107018467A patent/KR20100123835A/ko not_active Application Discontinuation
- 2009-02-18 AU AU2009215643A patent/AU2009215643A1/en not_active Abandoned
- 2009-02-18 BR BRPI0908815A patent/BRPI0908815A2/pt not_active IP Right Cessation
- 2009-02-18 CN CN2009801138321A patent/CN102007108A/zh active Pending
- 2009-02-19 TW TW098105199A patent/TW200948791A/zh unknown
-
2010
- 2010-07-26 ZA ZA2010/05314A patent/ZA201005314B/en unknown
- 2010-07-28 CR CR11604A patent/CR11604A/es not_active Application Discontinuation
- 2010-07-29 NI NI201000132A patent/NI201000132A/es unknown
- 2010-08-06 US US12/852,076 patent/US8268828B2/en active Active
- 2010-08-12 IL IL207597A patent/IL207597A0/en unknown
- 2010-08-18 EC EC2010010409A patent/ECSP10010409A/es unknown
- 2010-08-18 DO DO2010000254A patent/DOP2010000254A/es unknown
- 2010-08-18 SV SV2010003648A patent/SV2010003648A/es not_active Application Discontinuation
- 2010-08-19 CO CO10102315A patent/CO6241113A2/es not_active Application Discontinuation
- 2010-09-13 MA MA33173A patent/MA32191B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201005314B (en) | 2011-03-30 |
CA2715557A1 (en) | 2009-08-27 |
EP2262784B1 (en) | 2014-04-16 |
AU2009215643A1 (en) | 2009-08-27 |
PE20091576A1 (es) | 2009-11-05 |
US8268828B2 (en) | 2012-09-18 |
CL2009000368A1 (es) | 2009-06-26 |
IL207597A0 (en) | 2010-12-30 |
NZ587380A (en) | 2011-09-30 |
KR20100123835A (ko) | 2010-11-25 |
WO2009105435A1 (en) | 2009-08-27 |
JP2011512412A (ja) | 2011-04-21 |
MA32191B1 (fr) | 2011-04-01 |
AR070430A1 (es) | 2010-04-07 |
ECSP10010409A (es) | 2010-09-30 |
US20100305088A1 (en) | 2010-12-02 |
BRPI0908815A2 (pt) | 2019-09-24 |
RU2010138577A (ru) | 2012-03-27 |
TW200948791A (en) | 2009-12-01 |
EP2262784A1 (en) | 2010-12-22 |
NI201000132A (es) | 2011-03-16 |
SV2010003648A (es) | 2011-01-31 |
CN102007108A (zh) | 2011-04-06 |
CR11604A (es) | 2010-10-05 |
CO6241113A2 (es) | 2011-01-20 |
DOP2010000254A (es) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010008397A (es) | Inhibidores del receptor de quimioquinas cxcr3. | |
MX353257B (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
HRP20130797T1 (en) | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
ATE551059T1 (de) | Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie | |
WO2009027346A3 (de) | 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen | |
TW200602324A (en) | Tetrahydro-indazole cannabinoid modulators cross reference to related applications | |
EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
MX338489B (es) | Derivados de hidantoina utiles como inhibidores de kv3. | |
EP2603214A4 (en) | HETEROARYLE AND USES THEREOF | |
WO2010042636A3 (en) | Telomerase inhibitors and methods of use thereof | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
MX2009013353A (es) | Compuestos activadores de telomerasa y metodos para su uso. | |
EP2340258A4 (en) | PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES | |
EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
EA201000392A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
ES2377881T3 (es) | Inhibidores de Glepp-1 en el tratamiento de trastornos autoinmunes y/o inflamatorios | |
MA32933B1 (fr) | Combinaison d'inhibiteurs de hspo90 et d'herceptine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |